RxDoctor Payments Data

Lindsay Montgomery, PA

Physician Assistant · Ashland, KYNPI 1750692489

Payments from drug & device makers

$4,962in general payments, 2019–2025

Across 269 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$688
  • Pfizer$401
  • AbbVie$358
  • Johnson & Johnson$302
  • Antares Pharma, Inc.$301
  • Merck$209
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$4,68694%
  • Education$2766%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,962 in reported general payments places this provider in the 90th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$20,885
Medicare patients
220
Services billed
510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide11$154,916
MyrbetriqMirabegron131$106,337
GemtesaVibegron91$64,384
Tamsulosin Hcl527$6,750
Potassium Citrate ErPotassium Citrate24$5,807
Oxybutynin Chloride ErOxybutynin Chloride259$5,373
Finasteride230$1,966
Estradiol31$1,770
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst53$1,496
Tolterodine Tartrate ErTolterodine Tartrate16$1,494
Methenamine Hippurate28$1,440
Silodosin15$1,283
Bicalutamide35$830
Ciprofloxacin Hcl50$673
Cephalexin78$457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$688$261,252142 claims
Sumitomo Pharma America, Inc.Gemtesa$55$64,38491 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Ashland

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →